Professional
Added to YB: 2025-07-11
Pitch date: 2025-06-30
MEDCL.PA [bullish]
MedinCell S.A.
-2.87%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Market Cap
EUR 522.5M
Pitch Price
EUR 16.72
Price Target
N/A
Dividend
N/A
Sector
Pharmaceuticals
Category
growth
Show full summary:
Norbury Capital Portfolio Holding: MedinCell S.A.
MEDCL.PA: French biotech with BEPO technology for long-acting injectables (LAI). Partners with pharma cos, earning milestones + high single-digit royalties. Uzedy (schizophrenia) w/Teva could earn $100M royalties; Olanzapine LAI approval expected H2 2024 with $200M potential. AbbVie pipeline of 6 more drugs. Breakeven soon, €150M+ net income potential.
Read full article (2 min)